Use of a sustained-release formulation of oxprenolol and cyclopenthiazide ('Trasidrex') in the management of hypertension: a general practice study.

Abstract

An open study was carried out in general practice on 678 hypertensive patients being treated with a beta-blocker but who still had resting diastolic blood pressures greater than 100 mmHg. Previous treatment was stopped and substituted with 1 or 2 tablets daily of a fixed combination product containing 160 mg oxprenolol hydrochloride in a sustained-release formulation plus 0.25 mg cyclopenthiazide per tablet. After 4-weeks' treatment on this regimen, blood pressure levels fell significantly, from 179/108 mmHg to 155/93 mmHg, without any increase in the reporting of unpleasant side-effects.

• Authors: W A Forrest
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 6 Issue 8 Pg. 559-63 ( 1980) ISSN: 0300-7995 [Print] England
• PMID: 7389387 (Publication Type: Journal Article)

Chemical References

• Delayed-Action Preparations
• Diuretics
• Sodium Chloride Symporter Inhibitors
• Oxprenolol
• Cyclopenthiazide

Topics

• Adult
• Aged
• Blood Pressure (drug effects)
• Cyclopenthiazide (adverse effects, therapeutic use)
• Delayed-Action Preparations
• Diuretics
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Female
• Humans
• Hypertension (drug therapy)
• Male
• Middle Aged
• Oxprenolol (adverse effects, therapeutic use)
• Pulse (drug effects)
• Sodium Chloride Symporter Inhibitors (therapeutic use)